Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Italian Survey on adjuvant treatment of non-small cell lung cancer (ISA).
Banna GL, Di Maio M, Follador A, Collovà E, Menis J, Novello S, Bria E; ISA Co-Authors; Airoldi M, Amoroso D, Ardizzoia A, Aurilio G, Bajetta E, Ballardini P, Barbieri F, Barletta E, Balzelloni ML, Basso U, Bernardini I, Boni C, Bordin V, Bretti S, Bronte G, Brunetti C, Buti S, Capanna L, Colombo A, Condemi G, Cortinovis D, Dambrosio M, Di Fonzo C, Di Lucca G, Dima G, Falzetta A, Favaretto A, Ferraù F, Garetto L, Gebbia V, Genestreti G, Gentile AL, Giovanardi F, Labianca R, Lorusso V, Mantovani G, Martelli O, Massari F, Mazzoli M, Michetti G, Mordenti P, Mucciarini C, Munao S, Nacci A, Pogliani C, Procopio G, Riccardi F, Rizzato S, Rossi A, Rosti G, Russo P, Saladino T, Salesi N, Santangelo D, Sava T, Savarino A, Spinnato F, Tiseo M, Tomassi O, Tondulli L, Tonini G, Turano S, Valerio MR, Verderame F, Zanelli F, Zanon E. Banna GL, et al. Among authors: buti s. Lung Cancer. 2011 Jul;73(1):78-88. doi: 10.1016/j.lungcan.2010.10.020. Epub 2010 Dec 8. Lung Cancer. 2011. PMID: 21144614
Sunitinib, pazopanib or sorafenib for the treatment of patients with late relapsing metastatic renal cell carcinoma.
Santoni M, Conti A, Porta C, Procopio G, Sternberg CN, Basso U, De Giorgi U, Bracarda S, Rizzo M, Ortega C, Massari F, Iacovelli R, Derosa L, Masini C, Milella M, Di Lorenzo G, Atzori F, Pagano M, Buti S, De Vivo R, Mosca A, Rossi M, Paglino C, Verzoni E, Cerbone L, Muzzonigro G, Falconi M, Montironi R, Burattini L, Santini D, Cascinu S. Santoni M, et al. Among authors: buti s. J Urol. 2015 Jan;193(1):41-7. doi: 10.1016/j.juro.2014.07.011. Epub 2014 Jul 18. J Urol. 2015. PMID: 25046616
Surgical resection does not improve survival in patients with renal metastases to the pancreas in the era of tyrosine kinase inhibitors.
Santoni M, Conti A, Partelli S, Porta C, Sternberg CN, Procopio G, Bracarda S, Basso U, De Giorgi U, Derosa L, Rizzo M, Ortega C, Massari F, Iacovelli R, Milella M, Di Lorenzo G, Buti S, Cerbone L, Burattini L, Montironi R, Santini D, Falconi M, Cascinu S. Santoni M, et al. Among authors: buti s. Ann Surg Oncol. 2015;22(6):2094-100. doi: 10.1245/s10434-014-4256-7. Epub 2014 Dec 4. Ann Surg Oncol. 2015. PMID: 25472645
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy.
Santoni M, Buti S, Conti A, Porta C, Procopio G, Sternberg CN, Bracarda S, Basso U, De Giorgi U, Rizzo M, Derosa L, Ortega C, Massari F, Milella M, Bersanelli M, Cerbone L, Muzzonigro G, Burattini L, Montironi R, Santini D, Cascinu S. Santoni M, et al. Among authors: buti s. Target Oncol. 2015 Dec;10(4):517-22. doi: 10.1007/s11523-014-0356-3. Epub 2015 Jan 6. Target Oncol. 2015. PMID: 25559290
Risk of recurrence and conditional survival in complete responders treated with TKIs plus or less locoregional therapies for metastatic renal cell carcinoma.
Santini D, Santoni M, Conti A, Procopio G, Verzoni E, Galli L, di Lorenzo G, De Giorgi U, De Lisi D, Nicodemo M, Maruzzo M, Massari F, Buti S, Altobelli E, Biasco E, Ricotta R, Porta C, Vincenzi B, Papalia R, Marchetti P, Burattini L, Berardi R, Muto G, Montironi R, Cascinu S, Tonini G. Santini D, et al. Among authors: buti s. Oncotarget. 2016 May 31;7(22):33381-90. doi: 10.18632/oncotarget.8302. Oncotarget. 2016. PMID: 27027342 Free PMC article.
Clinical outcome of patients who reduced sunitinib or pazopanib during first-line treatment for advanced kidney cancer.
Iacovelli R, Cossu Rocca M, Galli L, De Giorgi U, Sabbatini R, Santoni M, Mosca A, Fornarini G, Massari F, Masini C, Bersanelli M, Biasco E, Lolli C, Guida A, Berardi R, Terrone C, Pastorino A, Ardizzoni A, Pinto C, Buti S, Nolè F, Tortora G. Iacovelli R, et al. Among authors: buti s. Urol Oncol. 2017 Sep;35(9):541.e7-541.e13. doi: 10.1016/j.urolonc.2017.05.007. Epub 2017 May 29. Urol Oncol. 2017. PMID: 28572027
Outcome of oligoprogressing metastatic renal cell carcinoma patients treated with locoregional therapy: a multicenter retrospective analysis.
Santini D, Ratta R, Pantano F, De Lisi D, Maruzzo M, Galli L, Biasco E, Farnesi A, Buti S, Sternberg CN, Cerbone L, Di Lorenzo G, Spoto S, Sterpi M, De Giorgi U, Berardi R, Torniai M, Camerini A, Massari F, Procopio G, Tonini G. Santini D, et al. Among authors: buti s. Oncotarget. 2017 Aug 7;8(59):100708-100716. doi: 10.18632/oncotarget.20022. eCollection 2017 Nov 21. Oncotarget. 2017. PMID: 29246014 Free PMC article.
304 results